

# Human Parthenogenetic Embryonic Stem Cell-Derived Neural Stem Cells Express HLA-G and Show Unique Resistance to NK Cell-Mediated Killing

Jessica Schmitt,<sup>1</sup> Sigrid Eckardt,<sup>2</sup> Paul G Schlegel,<sup>3</sup> Anna-Leena Sirén,<sup>4</sup> Valentin S Bruttel,<sup>5</sup>  
K John McLaughlin,<sup>2</sup> Jörg Wischhusen,<sup>5</sup> and Albrecht M Müller<sup>1</sup>

<sup>1</sup>Institute for Medical Radiology and Cell Research (MSZ) in the Center for Experimental Molecular Medicine (ZEMM), University of Würzburg, Würzburg, Germany; <sup>2</sup>Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America; <sup>3</sup>University Children's Hospital Würzburg, Pediatric Hematology/Oncology, Würzburg, Germany; <sup>4</sup>Department of Neurosurgery, and <sup>5</sup>University of Würzburg Medical School, Department of Obstetrics and Gynecology, Section for Experimental Tumor Immunology, University of Würzburg, Würzburg, Germany

Parent-of-origin imprints have been implicated in the regulation of neural differentiation and brain development. Previously we have shown that, despite the lack of a paternal genome, human parthenogenetic (PG) embryonic stem cells (hESCs) can form proliferating neural stem cells (NSCs) that are capable of differentiation into physiologically functional neurons while maintaining allele-specific expression of imprinted genes. Since biparental ("normal") hESC-derived NSCs (N NSCs) are targeted by immune cells, we characterized the immunogenicity of PG NSCs. Flow cytometry and immunocytochemistry revealed that both N NSCs and PG NSCs exhibited surface expression of human leukocyte antigen (HLA) class I but not HLA-DR molecules. Functional analyses using an *in vitro* mixed lymphocyte reaction assay resulted in less proliferation of peripheral blood mononuclear cells (PBMC) with PG compared with N NSCs. In addition, natural killer (NK) cells cytolyzed PG less than N NSCs. At a molecular level, expression analyses of immune regulatory factors revealed higher HLA-G levels in PG compared with N NSCs. In line with this finding, *MIR152*, which represses HLA-G expression, is less transcribed in PG compared with N cells. Blockage of HLA-G receptors ILT2 and KIR2DL4 on natural killer cell leukemia (NKL) cells increased cytolysis of PG NSCs. Together this indicates that PG NSCs have unique immunological properties due to elevated HLA-G expression.

Online address: <http://www.molmed.org>

doi: 10.2119/molmed.2014.00188

## INTRODUCTION

Mammalian parthenogenetic (PG) embryos undergo early developmental demise and do not develop to full term. However, PG human embryonic stem cells (hESCs) can be established from blastocysts originating from unfertilized oocytes that have been activated artificially (1–5). PG hESCs contain genetic material exclusively from the oocyte donor. Due to meiotic recombination, PG hESC derived from

human leukocyte antigen (*HLA*) heterozygous donors can be both *HLA* heterozygous and homozygous; and the induction of haploidy during oocyte activation protocols can be utilized to generate *HLA* homozygous PG hESC (6,7). Homozygous PG hESCs may serve as an alternative for immunomatched therapies for a large population of patients (8).

There is increasing evidence that paternally and maternally inherited alleles in-

fluence brain development, function and behavior (9). Therefore, PG hESCs are a unique model system to study the distinct roles of paternal and maternal genomes during neural development. Chimera studies in the mouse have shown that neural development requires tight control of imprinted gene expression: when combined with normal embryos to form chimeras, murine PG cells contributed preferentially to the cortex, striatum and hippocampus, but not to the hypothalamic structures (10). Conversely, androgenetic cells, with two copies of a paternal genome, were found in hypothalamic structures but not in the cortex. These experiments suggested that both parental genomes play nonredundant roles during brain development. However, uniparental murine and human ESCs resemble biparental ("normal") ESCs (N ESCs) in their capacity to proliferate and undergo

**Address correspondence to** Albrecht M Müller, Institute for Medical Radiation and Cell Research (MSZ) in the Center of Experimental Molecular Medicine (ZEMM), University of Würzburg, Zinklesweg 10, 97078 Würzburg, Germany. Phone: +49-931-201-45848; Fax: +49-931-201-45147; E-mail: [albrecht.mueller@uni-wuerzburg.de](mailto:albrecht.mueller@uni-wuerzburg.de).

Submitted September 20, 2014; Accepted for publication March 23, 2015; Published Online ([www.molmed.org](http://www.molmed.org)) March 23, 2015.

The Feinstein Institute  
for Medical Research 

Empowering Imagination. Pioneering Discovery.®

multilineage *in vitro* differentiation with similar functional neurogenesis and *in vivo* neural engraftment (1,11–14).

*In vitro* and *in vivo* studies revealed that N hESCs and hESC-derived progeny are not immune-privileged (15). N hESCs and their differentiated derivatives express low levels of HLA class I (HLA-I), which can be induced by interferon- $\gamma$  (IFN- $\gamma$ ), but they do not express costimulatory or HLA class II (HLA-II) molecules (16,17). Whether or not N hESCs stimulate allogeneic T cell proliferation remains contradictory (17,18). However, N hESC-derived neural stem cells (N NSCs) stimulate the proliferation of peripheral blood mononuclear cells (PBMCs) *in vitro*, particularly of CD4<sup>+</sup> T cells; N NSCs also are susceptible to natural killer (NK) cell-mediated lysis (19,20). *In vivo* analyses further showed that xeno-rejection of hESCs and of hESC-derived cells is mainly T cell-mediated and that NK cells also are involved (21,22).

The nonclassical HLA-Ib molecule HLA-G has been identified as a ligand that can induce tolerance. HLA-G has properties that differ from classical HLA-I molecules. Classical HLA molecules are highly polymorphic and, therefore, can present a wide range of antigenic peptides, whereas *HLA-G* displays only very limited polymorphism. The expression of *HLA-G* is restricted mainly to extravillous cytotrophoblast cells of the placenta with a role in maternal-fetal immunological tolerance during pregnancy (23,24). *HLA-G* mRNA also is present in human oocytes and preimplantation embryos, in tumor and in virus-infected cells, in the adult human brain and in mesenchymal stem cells (25–28). Inflammatory conditions induce HLA-G expression in microglia, macrophages and neurons to counteract inflammatory responses (29). A small number of HLA-G-expressing cells is sufficient to maintain an antiinflammatory milieu in the central nervous system (CNS) (29). Whether N hESCs express *HLA-G* remains unclear, as disparate results have been reported (16,30,31).

HLA-G inhibits T and NK cell proliferation, the cytolytic function of NK cells and alloproliferative responses of CD4<sup>+</sup>

T cells (24). HLA-G exerts its tolerogenic functions through direct binding to its inhibitory receptors ILT2 (on B, T and NK cells), ILT4 (on myeloid cells) and KIR2DL4 (on the CD56<sup>+</sup> subset of NK cells), even though the latter interaction has become controversial (24,32).

To validate that PG hESC-derived NSCs (PG NSCs) have no deficits in HLA biology it is critical to characterize their immunological properties in more detail. We therefore assessed HLA expression and function in PG and N NSCs using *in vitro* assays. We show that, in contrast to N-derived cells, PG NSCs exhibit elevated expression of HLA-G and thereby inhibit both the proliferation of PBMCs and cytolytic activity of NKL cells.

## MATERIALS AND METHODS

### Cell Lines and Culture

PG hESC lines LLC6P and LLC9P (previously pHESC-3 and pHESC-6) were obtained from the International Stem Cell Corporation (Carlsbad, CA, USA) (1). N hESC lines H9 (WiCell, Madison, WI, USA) (33) and HS401 (Karolinska Institute, Stockholm, Sweden) (34) were used as controls. PG and N hESC lines were cultured on feeders (human foreskin fibroblasts [ATCC-LGC Standards, Wesel, Germany] or murine embryonic fibroblasts) treated with mitomycin C (Sigma-Aldrich, St. Louis, MO, USA). Cells were differentiated into the neural lineage as described (12). Briefly, for embryoid body (EB) formation, detached hESCs were cultured for 4 d under floating conditions in KnockOut DMEM medium (Life Technologies [Thermo Fisher Scientific Inc., Waltham, MA, USA]) supplemented with 15% KnockOut Serum Replacement (Life Technologies [Thermo Fisher Scientific]), 10 mL/L penicillin/streptomycin, 2 mmol/L L-glutamate, 1% nonessential amino acids, 10 mmol/L HEPES (all from PAA Laboratories, Cölbe, Germany) and FGF2 (R&D Systems, Abingdon, UK). To generate attached EBs (attEBs), EBs were plated onto polyornithin/laminin-coated plates (polyornithin/laminin from Sigma-Aldrich) in N2 medium consisting of

DMEM/F-12 medium (Life Technologies [Thermo Fisher Scientific]), 10 mL/L penicillin/streptomycin and N2 supplement (1:100) (Life Technologies [Thermo Fisher Scientific]). 20 ng/mL fibronectin (Sigma-Aldrich) and 10 ng/mL FGF2 were added freshly. For expansion of attEBs of line LLC6P, 20 ng/mL laminin was added. After 10 d of culturing attEBs, rosette structures were isolated mechanically with a needle and isolates were propagated for 4 d as free-floating neurospheres in N2 medium supplemented with 10 ng/mL FGF2. Neurospheres were dissociated with trypsin/EDTA (GE Healthcare, Munich, Germany) and cells were seeded onto polyornithin/laminin-coated plates in N2 medium supplemented with 0.16 g/mL glucose (AppliChem, Darmstadt, Germany) to generate NSCs. Media with freshly added 10 ng/mL FGF, 10 ng/mL EGF (R&D Systems) and B27 supplement (1:100, Life Technologies [Thermo Fisher Scientific]) was changed every second day. For passaging, NSCs were dissociated with trypsin/EDTA. Trypsin inhibitor (Sigma-Aldrich) was added to stop the reaction. Cells were replated onto polyornithin/laminin-coated plates. IFN- $\gamma$  (Millipore, Schwalbach, Germany) treatment was done using 25 ng/mL for 48 h. EDTA (AppliChem) treatment was done using 1 mmol/L for 24 h.

The human CML cell line K562 and the human choriocarcinoma cell line JEG-3 were cultured in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% FCS (Life Technologies [Thermo Fisher Scientific]), 10 mL/L penicillin/streptomycin and 2 mmol/L L-glutamate. PBMCs, isolated by Ficoll-Paque (GE Healthcare) gradient centrifugation, were cultured in RPMI-1640 medium as detailed above.

### HLA Fine Typing

Feeder cells were depleted by repeated passages of PG and N hESCs onto Matrigel-coated plates (Matrigel from BD Biosciences, Heidelberg, Germany) using feeder-conditioned medium. For HLA fine typing, genomic DNAs of

PBMCs, feeder-depleted PG and N hESCs were isolated by phenol/chloroform extraction. HLA typing of PG and N hESCs required testing for HLA-A, -B, -C, -DRB1, and -DQB1 at high resolution as described previously (35). Exons 2 and 3 were analyzed for HLA class I typing, and exon 2 only for HLA class II typing. High resolution HLA typing was performed by sequencing analysis (sequence-based typing) for HLA class I and by polymerase chain reaction (PCR)-sequence-specific oligonucleotide probes method or sequence-based typing for HLA class II (35).

### Immunocytochemistry

Cells grown on coverslips or cytopun cells were fixed in 3.7% formaldehyde/PBS (formaldehyde from AppliChem) and were either permeabilized and blocked in PBS containing 0.1% Triton X-100 and 0.2% gelatin (both AppliChem) or in 1% gelatin/PBS. Staining was performed overnight at 4°C with the following primary antibodies: mouse anti-OCT3/4 (Santa-Cruz Biotechnology Inc., Dallas, TX, USA), mouse anti-*nestin* (Abcam, Cambridge, UK), rabbit anti-SOX1 (Millipore), mouse anti-HLA class I (clone W6/32, Abcam), mouse anti-HLA-DR (clone TAL14.1, Abcam). Cy3- or Cy5-labeled anti-mouse or Cy3-labeled anti-rabbit (Millipore) secondary antibodies were diluted in blocking solution and incubated (1 h, room temperature) with samples. DAPI (Sigma-Aldrich) was used to counterstain nuclei. Samples were mounted in ProLong Gold antifade reagent (Life Technologies [Thermo Fisher Scientific]) and analyzed using SP5 Confocal (Leica, Wetzlar, Germany) or AxioVision Microscopes (Carl Zeiss, Oberkochen, Germany). Images were processed using the ImageJ (NIH, Bethesda, MD, USA) or AxioVision software. To assess the pluripotent status of the cells, fixed hESCs were stained with the alkaline phosphatase kit from Sigma-Aldrich.

### Flow Cytometry

PG, N NSCs and control cells were trypsinized, resuspended in staining buffer (phosphate buffered saline [PBS]

with 0.4% BSA) and passed through a cell strainer (70  $\mu$ m) (BD Biosciences). Two  $\times 10^5$  PG, N NSCs or control cells were incubated for 1 h at 4°C with mouse anti-HLA class I (Abcam), mouse anti-HLA-DR (Abcam), mouse anti-HLA-DQ (clone T $\ddot{U}$ 169, Imusyn, Göttingen, Germany), DyLight 680 conjugated mouse anti-HLA-DP (clone B7/21, Leinco Technologies, St. Louis, MO, USA), APC-conjugated mouse anti-HLA-DR (clone L243, BioLegend, London, UK), APC-conjugated mouse anti-HLA-G (clone MEM-G/9, Life Technologies [Thermo Fisher Scientific]) or appropriate isotype control antibodies. Cells were washed and incubated (1 h, 4°C) with anti-mouse Cy3-labeled secondary antibody (Cy3 from Millipore). After staining, cells were washed and resuspended in staining buffer. Samples were analyzed on a FACSCanto flow cytometer (BD Biosciences). A live cell FSC/SSC gate was used. Data were analyzed using FlowJo software (Treestar, Ashland, OR, USA). Specific fluorescence indexes (SFIs) were calculated by dividing median fluorescence values of each specific antibody by the median fluorescence values of the respective isotype control reaction.

### Mixed Lymphocyte Reaction (MLR)

NSCs and control cells (PBMCs, JEG-3 cells) were irradiated (20 Gy; Faxitron CP-160 X-ray radiation cabinet [160 kV, 6.3 mA, 0.4 Gy/min, filter: 0.5 mm Cu]) and used as stimulator cells in a colorimetric MLR (Roche, Mannheim, Germany). In a 96-well flat bottom plate,  $1 \times 10^5$  PBMCs and  $1 \times 10^5$  irradiated stimulator cells were mixed and incubated. As a positive control, PBMCs in coculture with irradiated autologous PBMCs were treated with 2.5  $\mu$ g/mL concanavalin A (ConA) (Sigma-Aldrich) and 1% (v/v) phytohemagglutinin (PHA-M) (Life Technologies [Thermo Fisher Scientific]). Each experimental group was plated in triplicates. After 4 d, cocultures were incubated for 24 h with 10  $\mu$ mol/L bromodeoxyuridine (BrdU). Cells were fixed, incubated with blocking solution (Roche) and anti-BrdU-peroxidase, then washed

before 3,3',5,5'-tetramethylbenzidine (TMB), the visualizing reagent, was added. 1 mol/L H<sub>2</sub>SO<sub>4</sub> was added to stop the reaction. Enzymatic reactions were quantified in a SPECTRA Thermo enzyme-linked immunosorbent assay (ELISA) plate reader (Tecan Group Ltd., Männedorf, Switzerland) at 450 nm (reference wavelength 620 nm). Levels of background signals in unstimulated PBMCs and stimulator cells were subtracted.

### Cytotoxicity Assay

To assess the NSC-lysis ability of NKL cells, a nonradioactive cytotoxicity assay was used (Promega, Mannheim, Germany). NKL effector cells were cultured in RPMI-1640 medium supplemented with 10% FCS, 10% horse serum (Life Technologies [Thermo Fisher Scientific]), 10 mL/L penicillin/streptomycin, 2 mmol/L L-glutamate and 200 U/mL IL-2 (PeproTech, Hamburg, Germany). NKL cells were added to  $5 \times 10^4$  target cells to achieve 10:1 NKL-to-target cell ratios in a final volume of 100  $\mu$ L. Target cells (PG, N NSCs, or control cells [K562 and JEG-3]) and NKL cells were cultivated either alone or in coculture for 4 h at 37°C in polyornithin/laminin-coated plates in triplicates. Cells were centrifuged, supernatants were transferred into new plates and the substrate mix was added. After 30 min, the reaction was stopped and absorbance values that represent lactate dehydrogenase (LDH) activity were determined by SPECTRA Thermo ELISA plate reader at 490 nm. Background signals were subtracted and percentages of cytotoxicity were calculated with the following formula:

$$\% \text{ cytotoxicity} = \frac{\text{experimental} - \text{effector spontaneous} - \text{target spontaneous}}{\text{target maximum} - \text{target spontaneous}} \times 100,$$

where "experimental" is absorbance values from cocultures of effector and target cells, "effector spontaneous" or "target spontaneous" is spontaneous LDH release of cultured effector or target cells, and where "target maximum" is maxi-

mum LDH release in cultures of target cells after chemically-induced cell lysis.

### Detection of Active Caspase-3/7

For quantification of apoptotic cells, the CellEvent Caspase-3/7 Green Flow Cytometry Assay (Life Technologies [Thermo Fisher Scientific]) was used. Target cells (PG or N NSCs) were labeled with 5  $\mu\text{mol/L}$  Cell Proliferation Dye eFluor670 (eBioScience, Frankfurt, Germany) to distinguish target and effector cells. To assess specific binding of HLA-G to NKL receptors, NKL cells were preincubated for 30 min with 0.1  $\mu\text{g/mL}$  of functional blocking monoclonal antibodies raised against the inhibitory NKL receptors ILT2 (HP-F1, eBioscience) or KIR2DL4 (clone mAb 33, BioLegend). Next,  $5 \times 10^4$  labeled target and  $5 \times 10^5$  effector NKL cells were cocultured in RPMI-1640 medium supplemented with 10 mL/L penicillin/streptomycin and 2 mmol/L L-glutamate for 4 h at 37°C, 5% CO<sub>2</sub>. Cells were trypsinized and stained (30 min, 37°C) with 0.5  $\mu\text{mol/L}$  CellEvent Caspase-3/7 green detection reagent. Samples were measured in a FACSCanto. Data were analyzed using FlowJo software. A live cell gate on APC/FSC channel was used to select for highly cell proliferation dye-positive target cells.

### Semiquantitative Reverse Transcriptase (RT)-PCR

Total RNAs were isolated from feeder-depleted PG and N hESCs and from differentiated progeny using peqGOLD RNAPure (Peqlabs, Göttingen, Germany). RNAs were treated with DNase I (Applied Biosystems [Thermo Fisher Scientific]) and 1  $\mu\text{g}$  RNA was reverse transcribed using M-MLV reverse transcriptase (Life Technologies [Thermo Fisher Scientific]). As controls, cDNAs were generated from human fetal brain total RNA (19 wks, male, single donor) (Agilent Technologies, Santa Clara, CA, USA) and from PBMCs, JEG-3 and K562 cells. For amplification, Taq Polymerase (H T Biotechnology, Cambridge, UK) was used. PCR conditions were: 94°C, 30 s, 56.5°C to 62°C, 30 s according to the

primers, 72°C, 30 s (28 to 38 cycles). *RPL30* was used as housekeeper control. Primers (Eurofins MWG Operon, Ebersberg, Germany) used were: *OCT4* forward (frw): 5'-AGCCCTCATTTACCAGGCC-3', reverse (rev): 5'-CAAAACCCGGAGGAGTCCA-3', 62°C; *REX1* frw: 5'-TAGAATGCGTCATAAGGGGTGA-3', rev: 5'-TCTTGCCGTGCATGTACTCAGAA-3', 57°C; *CD40* frw: 5'-ACCCTTGAGAACAGGATCCCGAAG-3', 57.5°C; *CD80* frw: 5'-TGCTGGCTGGTCTTCTCAC-3', rev: 5'-GGTTCCTGTCTCGGGCCAT-3', 56.5°C; *CD84* frw: 5'-ATCCAAGAACCACGGCAAGT-3', rev: 5'-CTCCTGCGTCTTCCATCCTC-3', 57.5°C; *CD86* frw: 5'-CTGCTCATCTATACACGGTACC-3', rev: 5'-GGAAACGTCTACAGTCTGTG-3', 60.6°C; *B7H1* frw: 5'-TTTGCTGAACGCCCATACA-3', rev: 5'-TTGGTGGTGGTGGTCTTACC-3', 57.5°C; *2B4* frw: 5'-TCGTGATTCTAAGCCACTGT-3', rev: 5'-CAGGTTCTTGTGACGTGGGAG-3', 60.6°C; *HLA-DP* frw: 5'-AGGAATGCTACGCGTTAAT-3', rev: 5'-CAGCTCGTAGTTGTGCTGCTGC-3', 56.6°C; *HLA-DQ* frw: 5'-CTTGTGACCA GATACATCTA-3', rev: 5'-GGTCGTGCGGAGCTCCAAC-3', 57.8°C; *HLA-DR* frw: 5'-GCGGTTGCTGGAAAGATGCA-3', rev: 5'-GTGAAGCTCTACCAACCCC-3', 57.8°C; *RPL30* frw: 5'-ACAGCATGCGGAAAATACTAC-3', rev: 5'-AAAGGAAAATTTGTCAGGTTT-3', 60°C.

### Real-Time RT-PCR

As described above, 1  $\mu\text{g}$  RNA was reverse transcribed into cDNA. For mature miRNA analysis, 4  $\mu\text{g}$  RNA were reverse transcribed. For the formation of stem-loop structures, a gene-specific RT primer was added during cDNA synthesis (36). RT-PCR reactions were performed and quantified using ABsolute QPCR SYBR Green Mix (ABgene, Hamburg, Germany) and Rotor-Gene 3000 (Corbett Life Science, LTF Labortechnologie, Wasserburg, Germany). Real-time RT-PCR conditions were: 95°C, 45 s, 60°C, 40 s and 72°C, 60 s (35 cycles). Relative gene expression levels were calculated with the 2<sup>- $\Delta\Delta\text{Ct}$</sup>  method. The housekeeping gene *RPL30* was used

as reference, whereas for mature miRNA detection small nuclear RNA *U6* was used. Primer sequences were: *HLA-G* frw: 5'-TGCTGAGATGGAAGCAGTCTTC-3', rev: 5'-ACTACAGCTGCAAGGACAACA-3'; *MIR152* frw: 5'-GTCGTCAGTCATGACAGAACTT-3', rev: 5'-GTGCA GGGTCCGAGGT-3'; *U6* frw: 5'-CTCGC TTCGGCAGCACA-3', rev: 5'-AACGC TTCACGAATTTGCGT-3'.

### Western Blotting

For Western blotting,  $1 \times 10^6$  cells were lysed in 120  $\mu\text{L}$  6  $\times$  SDS loading buffer (0.5 mol/L Tris pH 6.8 buffer containing 0.4% SDS, 33% glycerol, 0.4 mol/L  $\beta$ -mercaptoethanol and bromphenolblue) (all from Sigma-Aldrich). Extracts were heated (95°C, 5 min). Discontinuous SDS-PAGE was performed using 12% acrylamide resolving and 4% to 5% stacking gel. Following electrophoresis, proteins were electroblotted onto Nitrocellulose membranes (GE Healthcare). Membranes were washed three times with PBS + 0.1% Tween-20 (PBST) (AppliChem) and blocked with 5% non-fat dry milk/PBST solution (milk from AppliChem) for 1 h at room temperature. Staining with primary anti-HLA-G MEM-G/1 (1:200, AbD Serotec by Bio-Rad, Puchheim, Germany), anti-GAPDH (Merck Millipore, Darmstadt, Germany); or anti-actin (1:1000, Santa Cruz Biotechnology) antibodies was performed at 4°C overnight. Membranes were washed three times in PBST and incubated with stabilized peroxidase-conjugated goat anti-mouse (H + L) secondary antibody (1:1000; Thermo Scientific [Thermo Fisher Scientific]) or goat anti-rabbit secondary antibodies (1:1250; Thermo Scientific [Thermo Fisher Scientific]) for 1 h at room temperature. Membranes were again washed three times before incubation with Immobilon Western HRP Substrate (Millipore) for 1 min. Immunoreactive protein bands were visualized by autoradiography (Bio-Rad, München, Germany). HLA-G blots were stripped and re probed for staining with an anti-GAPDH or anti-actin antibody as loading control.

### Transfection with MIR152 Mimic

For transfection,  $2 \times 10^5$  PG NSCs were plated onto polyornithin/laminin-coated 6-well plates. On the next day, cells were transfected with 5  $\mu\text{mol/L}$  MIR152 synthetic RNA duplex (MIR152 mimic) or with 5  $\mu\text{mol/L}$  anti-GAPDH RNA duplex (control) using Dharmafect transfection medium (Thermo Scientific [Thermo Fisher Scientific]). Fifty-six hours after transfection, cells were stained for FACS analysis, or RNA and protein were isolated.

### Bisulfite Sequencing

Bisulfite-modified DNA from PG and N NSCs was prepared using the EZ DNA Methylation-Direct kit (Zymo Research, Irvine, TX, USA). DNA fragments covering a region of 26 CpGs within the MIR152 promoter were amplified by PCR using frw 5'-GGGTTAGGGGAGTAGTAAAT-3' and rev 5'-TTCCTCAACTAATCCCTAAC-3' primers as described previously (37). PCR fragments were subcloned into pJET 2.1 (Thermo Scientific [Thermo Fisher Scientific]) for sequencing. Analysis of sequences and diagram generation was performed using BISMA (38).

### Statistical Analysis


Data are presented as mean  $\pm$  SD for the indicated number of biological replica (n). Data plotting and statistical analysis were done using Student *t* test (two-tailed, paired). Differences were considered significant at  $p < 0.05$ .

All supplementary materials are available online at [www.molmed.org](http://www.molmed.org).

## RESULTS

### PG hESC-Derived NSCs Express HLA-I but Not HLA-DR Antigens

PG hESCs exhibited typical hESC morphology, expressed pluripotency-related markers and formed neural rosettes and NSCs when subjected to a multistep differentiation protocol (Figures 1A, B, Supplementary Figure 1) as described previously (12). HLA fine typing revealed that the PG hESC lines used



**Figure 1.** Differentiation of PG hESCs into NSCs and expression of HLA and costimulatory molecules. (A) Phase contrast images of different stages during *in vitro* neural differentiation: (a) PG hESCs on feeders, (b) floating EBs, (c) attEBs (arrows indicate rosette-like structures), (d) floating neurospheres and (e) NSCs. Scale bar: 0.15 mm. Magnification showed NSCs. Scale bar: 0.1 mm. (B) Confocal images of NSC cultures immunostained with NSC-specific markers SOX1 (red) and Nestin (green) in PG and control N NSCs. Scale bar: 50  $\mu\text{m}$ . (C) Flow cytometry of untreated (left) or 48 h IFN- $\gamma$ -treated (25 ng/mL) (right) NSC cultures. Cells were stained with monoclonal antibodies specific for HLA class I or HLA-DR. Histograms show specific fluorescence signal for HLA class I or -DR (black lines) compared with isotype control (filled gray). Specific fluorescence indexes (SFI: specific geometric median/geometric median of unspecific control) are indicated in the upper right. (D) RT-PCR analysis for expression of costimulatory molecules in untreated PG and N NSCs and in IFN- $\gamma$  treated NSCs. JEG-3 cells and PBMCs were shown as controls and RPL30 as housekeeper gene.

**Table 1.** Isotype classification of PG and N hESCs.<sup>a,b</sup>

	HLA-I			HLA-II	
	HLA-A	HLA-B	HLA-C	HLA-DRB1	HLA-DQB1
HS401 hESCs	*01:01 *24:02	*07:02 *57:01	*07:01 *07:02	*07:01 *15:01	*03:03 *06:02
H9 hESCs	*02:01 *03:01	*35:03 *44:02	*04:01 *07:04	*15:01 *16:01	*05:02 *06:02
LLC9P hESCs	*02:01 *03:01	*07:02 *27:05	*02:02 *07:02	*04:04 *15:01	*06:03 *03:02
LLC6P hESCs	*02:01 *03:01	*52:01 *55:01	*03:03 *04:01	*01:01 *03:01	*02:01 *05:01
PBMCs	*02:01 *03:01	*40:01 *44:03	*03:04 *16:01	*11:01 *13:01	*03:01 *06:01

<sup>a</sup>HLA fine-typing of PG and N hESCs and PBMCs was performed by PCR.

<sup>b</sup>The alleles examined were in HLA-I and -II loci (HLA-A, -B, -C, -DRB1 and DQB1).

in this study were fully heterozygous in the HLA region (Table 1). To assess the expression of HLA-I and HLA-II molecules in PG in comparison to N NSCs, we used the W6/32 monoclonal antibody (mAb) directed against HLA class I and the TAL14.1 mAb recognizing HLA-DR beta. Flow cytometry and immunofluorescence staining of NSCs derived from 2 PG and 2 N control hESC lines revealed relatively low expression of HLA-I and absence of HLA-DR (Figure 1C, Supplementary Figures 2, 3). In addition, HLA-DP and -DQ were not expressed in PG or N NSCs (see Supplementary Figure 3). To assess the induction of HLA-I protein expression in NSCs, we treated the cells with IFN- $\gamma$ . Following treatment with IFN- $\gamma$ , both PG and N NSCs exhibited 12- to 50-fold elevated HLA-I expression (see Figure 1C, Supplementary Figure 2) but remained negative for HLA class II (see Figure 1C, Supplementary Figure 3). Expression of costimulatory molecules including *CD80*, *CD84*, *CD86*, *CD40*, *B7H1* and *2B4* that are required for T cell activation in addition to HLA binding was not detectable by RT-PCR in PG or N NSCs prior to or following IFN- $\gamma$  stimulation (Figure 1D).

### PG NSCs Are Less Immunogenic than N NSCs

N NSCs induce proliferation of allogeneic T cells in a mixed lymphocyte re-


action (MLR) despite the absence of costimulatory molecules (19,20). To address this property for PG NSCs, we recorded the response of healthy donor PMBCs to irradiated PG NSCs in allogeneic MLR reactions. Stimulated PBMCs were included as a positive control and JEG-3 cells, which suppress proliferative responses by surface HLA-G, as a negative control (39). As shown in Figure 2A, unstimulated PG and N NSCs only moderately induced proliferation of PBMCs, probably due to their low HLA-I and absent HLA-II expression. As IFN- $\gamma$  treatment induced HLA-I protein levels on NSCs (see Figure 1C), we next treated PG and N NSCs with IFN- $\gamma$  prior to PBMC coculture. IFN- $\gamma$ -treated PG NSCs stimulated the proliferation of PBMCs, but less strongly than N NSCs (see Figure 2A). We observed similarly low levels of stimulation with PBMCs from all blood donors tested; therefore, these coculture assays suggested either reduced immunogenicity or stronger immunosuppressive properties of PG NSCs. We further investigated NK cell-mediated target cell killing, which, depending on the balance of stimulatory and inhibitory ligands on target cells, can lead to rejection of allogeneic cells. The lack of HLA-I protein expression can render NSCs a target for NK cell-mediated cytotoxicity (40). To test whether NK cells target PG NSCs, we performed cytotoxicity assays using NK cells as effector cells, and

JEG-3 and NK cell-sensitive K562 cells as negative and positive controls, respectively. At an NK cell-to-target ratio of 10:1, N NSCs were more than three-fold more susceptible to NK cell lysis than PG NSCs (Figure 2B).

### HLA-G in PG NSCs Protects against NK-Induced Apoptosis

HLA-I and HLA-G are known ligands for inhibitory NK cell receptors such that higher expression of HLA-I or HLA-G ligands on PG NSCs could cause reduced NK cell-mediated cytotoxicity. Because PG and N NSCs express similar levels of HLA-I (see Figure 1C), we focused on HLA-G, which has been shown to reduce immune responses when expressed constitutively in hESC-derived dopaminergic neurons or in mesenchymal stem cells (28,41). To test whether PG in comparison to N NSCs have altered HLA-G expression leading to reduced immunogenicity, we first performed *HLA-G*-specific gene expression analysis. As shown in Figure 3A, *HLA-G* transcript levels were low in human PBMCs, fetal brain, N, PG hESCs and in N NSCs, but elevated in PG NSCs (see Figure 3A). *HLA-G* mRNA in PG NSCs was expressed at 10% to 20% of JEG-3 levels, a cell line known for its extremely high *HLA-G* expression, and at about 10-fold lower amounts in N NSCs (1% to 3%; see Figure 3A). Western blotting and flow cytometry revealed minor differences in HLA-G protein levels between PG and N NSCs (Figures 3B, C). Western analysis was consistent with the size of HLA-G1 (39 kDa) (see Figure 3B).

Next, to determine the function of HLA-G during the interaction of immune cells with allogeneic, hESC-derived NSCs, we analyzed apoptotic mechanisms. Flow cytometric detection of activated caspase-3 and -7 in PG and N NSCs following coculture in a 10:1 ratio was performed. Consistent with reduced NK cell-mediated lysis of PG NSCs (see Figure 2B), PG cells exhibited reduced caspase-3/7 activity compared with N NSCs (Figure 4). Interaction of HLA-G with the inhibitory NK receptors



**Figure 2.** Immunostimulatory properties of PG NSCs. (A) Cell proliferation in mixed lymphocyte reaction with irradiated autologous PBMCs ( $\Delta$ ), PG ( $\square$ ) or N ( $\circ$ ) NSCs as stimulator cells and PBMCs as responder cells at a 1:1 stimulator-to-responder ratio. Proliferation was measured by BrdU incorporation and ELISA. For maximum stimulation, a PBMC sample was treated with ConA and PHA (stimulated auto,  $\nabla$ ). \* $p < 0.05$  by Student  $t$  test. We analyzed three different donor samples (each sample was analyzed two to three times). Shown are the median for each condition. (B) Cytotoxicity assay. NKl effector cells were mixed with JEG-3 cells ( $\diamond$ ), K562 ( $\Delta$ ), N ( $\circ$ ) or PG NSCs ( $\square$ ) at 10:1 NKl-to-target ratios. NKl cell-mediated lysis was determined by lactate dehydrogenase release into the medium quantified by ELISA. \*\* $p < 0.001$ .  $n = 5$ .

ILT2, ILT4 or KIR2DL4 can inhibit the cytolytic function of NK cells (24). Therefore, we asked whether different HLA-G levels in PG and N NSCs caused the observed differences in susceptibility to NKl cell lysis. As shown in Figure 4, masking the inhibitory NKl receptors ILT2 or KIR2DL4 with functional blocking antibodies during coculture of NKl and target cells increased caspase-3/7 activity in PG NSC cultures. In N NSC cul-


tures, blockage of ILT2 or KIR2DL4 had, however, no effect on NKl-induced apoptosis. We refrained from also blocking ILT4 because this receptor is not expressed by NKl cells. Thus, masking of inhibitory NKl receptors leads to increased apoptosis of PG but not N NSCs after NKl exposure, suggesting a specific role of the ILT2 and KIR2DL4 ligand HLA-G in protecting PG NSCs against NKl cell lysis.

### MIR152 Regulates HLA-G Expression in PG NSCs

As the promoter region for *HLA-G* with its variable sites has not yet been characterized in detail, a potential regulation of *HLA-G* by promoter methylation could not be assessed. *HLA-G* is, however, a known target of *MIR152*, a microRNA which downregulates *HLA-G* expression and decreases ILT2-mediated inhibition of NK cell-mediated cytotoxicity (42). Real-time RT-PCR analysis to determine whether differences in *HLA-G* expression in PG and N NSCs correlated with the respective *MIR152* levels confirmed lower expression levels of *MIR152* in PG compared with N NSCs (Figure 5A). To perform gain-of-function analyses, we overexpressed *MIR152* in PG NSCs. As shown in Figure 5B, overexpression of *MIR152* in PG NSCs decreased *HLA-G* expression, while transfection of an unrelated RNA mimic did not affect *HLA-G* levels. This indicates that *HLA-G* expression is regulated by *MIR152* in NSCs. Due to the different expression levels of *MIR152* in PG and N NSCs, we hypothesized that *MIR152* expression may be subject to parent-of-origin-specific regulation. Bisulfite sequencing of the *MIR152* promoter region, however, did not reveal differences in CpG methylation between PG and N NSCs (Figure 5C). The observed differential expression of *MIR152* in PG and N NSCs is therefore independent of promoter DNA methylation.

### DISCUSSION

Our objective was to characterize *HLA* expression and function in PG NSCs. In summary, we observed that PG NSCs, which contain only maternally derived genomes, and N NSCs both express *HLA-I* proteins. Surprisingly, however, PG NSCs express high levels of *HLA-G*, a nonclassical *HLA* molecule that is expressed in a limited range of cell types. Functional immunological analyses revealed that, compared with N NSCs, PG NSCs stimulated less proliferation of allogeneic PBMCs. It is highly plausible that the impaired T cell proliferation is




**Figure 3.** HLA-G expression in PG NSCs. (A) *HLA-G*-specific RT-PCR analysis of human K562 CML cells, PBMCs, fetal brain (19 wks of gestation), N and PG hESCs and NSCs. Samples were normalized to the housekeeper gene *RPL30*. Relative gene expression levels were determined using the  $2^{-\Delta\Delta Ct}$  method; *HLA-G* gene expression in human JEG-3 cells was set to 1.  $**p < 0.001$ ;  $n = 3$ . (B) Western blot analysis to determine HLA-G protein levels in PG and N NSCs (antibody: MEM-G/1). GAPDH was used as loading control (left panel). Densitometric analysis of three independent Western blots was performed using ImageJ. HLA-G protein levels were normalized to GAPDH.  $*p < 0.05$  (right panel). (C) Flow cytometry of untreated (upper panel) or 24-h EDTA-treated (1 mmol/L) (lower panel) NSC cultures. Cells were stained with the HLA-G-specific antibody MEM-G/9. Histograms show specific fluorescence signal for HLA-G (black lines) compared with isotype control (filled gray). Specific fluorescence indexes (SFI: specific geometric median/geometric median of unspecific control) are indicated in the upper right.

linked to the presence of HLA-G, though this link was not ultimately proven by direct blocking experiments. Blockage of HLA-G receptors ILT2 and KIR2DL4 confirmed that high HLA-G expression levels decreased the susceptibility of PG NSCs toward NKL cell lysis.

Similar to earlier reports on N hESCs and their differentiated progeny, we observed that PG NSCs expressed low levels of HLA-I proteins but no HLA-II or costimulatory molecules (16,18,19). HLA-I expression in PG NSCs was increased by IFN- $\gamma$  treatment and reached PBMC levels as reported for N hESCs (16). Thus, HLA-I molecules are expressed on the surface of PG NSCs. The absence of HLA-II and costimulatory molecules on PG and N NSCs predicts that these cells do not deliver appropriate stimulatory signals for robust immune responses by direct allorecognition (16,17).

The status of HLA-G expression in N hESCs and their progeny remains unclear as the literature reports conflicting results. One report concluded that HLA-G is not expressed on N hESCs or differentiated progeny (16). Others showed that functionally active HLA-G is expressed (30,31). However, these discrepant results were generated using different hESC lines and different HLA-G antibodies. Despite substantial variation among pluripotent cell lines, the cell lines used in the present study showed similar results (43). In particular, this relates to *HLA-G* being expressed at higher levels in PG compared with N cells. Our analysis did not discriminate between the differentially spliced membrane-bound and soluble HLA-G isoforms, as all of these forms are immunosuppressive (30). Likewise, we did not test to which extent HLA-G on PG NSCs was bound to  $\beta$ 2-microglobulin ( $\beta$ 2M). Of note, free HLA-G also can engage the inhibitory receptor ILT4. Moreover, there is no neutralizing antibody for free HLA-G available (compare patent application WO2014072534A1/EP 2730588 A1, published May 14, 2014). Western blotting revealed a predominance of HLA-G1 in both N and PG NSCs as reported previously for N hESCs (31). The





**Figure 4.** Increased apoptosis in PG NSCs after blockage of inhibitory NKL receptors. Flow cytometric analysis of activated caspase-3/7 in the target cells PG (□) or N (○) NSCs, co-cultures of effector NKL cells and target cells (E:T) at 10:1 NKL-to-target ratios, E:T in the presence of blocking ILT2 antibody (E:T anti-ILT2) or KIR2DL4 antibody (E:T anti-KIR). \*\*\* $p < 0.0001$ , not significant (ns);  $n \geq 5$ .

elevated *HLA-G* levels in PG compared with N NSCs may be caused by parent-of-origin-specific mechanisms. Although a small number of genes are imprinted, these genes have important effects on development and physiology, and many are expressed in the brain (9). Earlier analyses revealed that, in first trimester trophoblast and placental cells, *HLA-G* is expressed from both alleles (44,45). However, for most tissues, allele specificity of expression has not yet been determined.

*HLA-G* expression underlies post-transcriptional regulation. Overexpression of *MIR152* revealed that *MIR152* targets and downregulates *HLA-G* expression and thereby sensitizes cells to NK cell-mediated killing (36,42). Low levels of *MIR152* were found in tumors with elevated *HLA-G* expression, such as glioblastoma (46,47). We show that *MIR152* expression levels were lower in PG compared with N NSCs and that overexpression of *MIR152* in PG NSCs reduced *HLA-G* protein levels. Although bisulfite analyses of the *MIR152* promoter did not reveal differential methylation patterns between PG and N cells, differential DNA methylation may occur at distant regions controlling *MIR152* ex-

pression. Therefore, our data support a model that includes *MIR152* as a regulator of *HLA-G* expression.


*HLA-G* expression in fetal cells of the placenta has been associated with inhibition of the maternal immune system. Its presence in other fetal tissues indicates additional roles during development (30); for example, *HLA-G* expression in primitive erythroid cells throughout prenatal life suggests a possible role in erythroid differentiation and angiogenesis (48).

In agreement with elevated *HLA-G* levels, PG NSCs were recognized by allogeneic immune cells but at reduced levels compared with N NSCs. At the maternal-fetal interface, *HLA-G* suppresses a wide range of immune responses by binding to the inhibitory receptors ILT2, ILT4 and KIR2DL4 (24). Antibody-mediated masking of either ILT2 or KIR2DL4 prior to *HLA-G* binding resulted in increased apoptosis of PG NSCs, further supporting the notion that *HLA-G* molecules on PG NSCs can functionally activate inhibitory NK cell receptors. Blockade of ILT4 was not investigated since this receptor is not expressed on NKL cells.

Parent-of-origin effects influence the etiology of multiple sclerosis as the pa-

ternally expressed *DLK1* was identified as a novel disease-predisposing gene in an autoimmunity encephalomyelitis model in rat (49). Our data show that the presence of maternal-only genomes in neural cells is associated with more pronounced *HLA-G* expression, suggesting higher *HLA-G*-mediated immune tolerance. The function of *HLA-I* proteins is, however, not limited to the immune system. *HLA-I* proteins also have been found to participate in brain development and plasticity and to regulate synaptic development and function of cortical connections in the developing mouse brain (50). Our observation that *HLA-G* is transcribed in the human fetal brain and that *HLA-G* expression is up-regulated during neural hESC differentiation indicates that *HLA-G* may also play a role during early developmental stages in the human brain, possibly via interaction with its receptor ILT2, which is expressed on microglial cells (51).

The brain is often considered an immune-privileged tissue. However, potent immune reactions occur in the central nervous system (52). *HLA-G* as a tolerogenic molecule could be employed in therapeutic applications. Along this line, hESC-derived dopaminergic neurons with stable *HLA-G* expression elicited a far lower immune response than non-transgenic hESC derivatives (41). *HLA-G* is also a key immunomodulatory molecule expressed by hESC-derived mesenchymal progenitors (53). In addition to the immunomodulatory functions of *HLA-G* in respect to NK cells, other aspects determine the fate of transplanted stem cells. For example, NSCs secrete paracrine factors including transforming growth factor (TGF)- $\beta$ 1, prostaglandins (PGE2), nitric oxide (NO) and heme oxygenases (HOs) (54). TGF- $\beta$ 1 maintains immune tolerance, T-cell homeostasis and balances the immunogenicity of NSCs (20,55,56). In addition, HOs alone or in combination with NO production mediate immunosuppressive effects of NSCs (57,58), and growth factors and neurotrophins influence stem cell-immune cell interactions (54). Also im-



**Figure 5.** *MIR152* expression in PG NSCs. (A) Real-time RT-PCR analyses of *MIR152* expression in PG and N NSCs normalized to the housekeeper gene *U6*. Gene expression was calculated with the  $2^{-\Delta\Delta Ct}$  method; *MIR152* gene expression in PBMCs was set to 1.  $**p < 0.001$ ;  $n = 3$ . (B) Overexpression of *MIR152* in LLC9P NSCs. Western blot analysis of HLA-G (MEM-G/1) in PG (LLC9P) NSCs transfected with anti-*GAPDH* (control) or *MIR152* mimic double-stranded oligonucleotides. Actin was used as loading control (left panel). Densitometric analysis of three independent western blots was performed using ImageJ. HLA-G protein levels were normalized to actin.  $*p < 0.05$  (right panel). (C) Analysis of CpG methylation of the *MIR152* promoter in PG and N NSCs. F1 represents the genomic region selected for bisulfite sequencing. Each row represents a separate DNA molecule (clone); CpG numbers are indicated on top. Gray and black boxes represent unmethylated and methylated CpG dinucleotides, respectively; white boxes: no data. Percentages of CpG methylation are indicated.  $n = 2$ .

immune-independent parameters, such as the ability to cope with oxidative stress, are critical for stem cell survival *in vivo* (59). Thus, the survival of transplanted NSCs is influenced by multiple factors, and a better understanding of the mechanisms of, for example, inflammatory cascades induced by transplanted NSCs is essential for the development of stem cell-based therapies for the brain (60).

Obviously, the best test for the immunogenicity of hESC-derived cells would require *in vivo* analyses. However, due to the lack of a murine HLA-G homologue and the lack of a suitable transplant model with a functional human immune system, *in vivo* testing of HLA-G function is difficult to perform and not always conclusive. Considering the difficulties with humanized animal models, we decided not to develop *in vivo* approaches and performed *in vitro* assays exclusively involving human cells. We conclude that *in vitro*, PG NSCs were found to express HLA-G and to be protected against NK cell-mediated lysis in an HLA-G dependent manner. Therefore, PG cells may be an alternative to transgenic HLA-G cells to alleviate or even avoid immune rejection in allogeneic therapies.

## CONCLUSION

In summary, PG hESC-derived NSCs with a maternally derived genome exhibit reduced immunogenicity due to elevated HLA-G expression, further enhancing the application of PG hESCs as a possible source of transplantation-based stem cell therapies. Furthermore, PG hESCs are a unique tool to investigate parent-of-origin-specific expression of HLA encoding genes.

## ACKNOWLEDGMENTS

We thank Ruslan Semechkin for kindly providing the PG hESCs LLC6P and LLC9P (International Stem Cell Corporation), Outi Hovatta and Liselotte Antonsen (Division of Obstetrics and Gynecology, Karolinska Institutet, Stockholm, Sweden) for the HS401 hESCs, WiCell Research Institute Wisconsin (Madison,

USA) for the H9 hESCs, Ulrike Kämmerer (Department of Obstetrics and Gynecology, University of Würzburg, Germany) for the JEG-3 cells and Winfried S Wels (Georg-Speyer-Haus, Frankfurt am Main, Germany) for the NKL cell line. We are grateful to Andrea Reusch and Doris Heim (MSZ, Würzburg, Germany) for technical assistance, and to Andrea Niklaus and Katharina Mattenheimer (ZEMM, Würzburg, Germany) for help with sample collection. We thank Joannis Mytilineos (Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, Germany) for high-resolution HLA typing. Funding for this work was provided by the Interdisciplinary Center for Clinical Research (IZKF), University of Würzburg (TP D103), DFG-funded SPP 1738 and by a fellowship, Chancengleichheit für Frauen in Forschung und Lehre, from the University of Würzburg (Würzburg, Germany).

## DISCLOSURE

The authors declare they have no competing interests as defined by *Molecular Medicine*, or other interests that might be perceived to influence the results and discussion reported in this paper.

## REFERENCES

- Revazova ES, et al. (2007) Patient-specific stem cell lines derived from human parthenogenetic blastocysts. *Cloning Stem Cells*. 9:432–49.
- Mai Q, et al. (2007) Derivation of human embryonic stem cell lines from parthenogenetic blastocysts. *Cell Res*. 17:1008–19.
- Lin G, et al. (2007) A highly homozygous and parthenogenetic human embryonic stem cell line derived from a one-pronuclear oocyte following in vitro fertilization procedure. *Cell Res*. 17:999–1007.
- Kim K, et al. (2007) Recombination signatures distinguish embryonic stem cells derived by parthenogenesis and somatic cell nuclear transfer. *Cell Stem Cell*. 1:346–52.
- Brevini TA, et al. (2009) Cell lines derived from human parthenogenetic embryos can display aberrant centriole distribution and altered expression levels of mitotic spindle check-point transcripts. *Stem Cell Rev*. 5:340–52.
- Revazova ES, et al. (2008) HLA homozygous stem cell lines derived from human parthenogenetic blastocysts. *Cloning Stem Cells*. 10:11–24.
- Turovets N, et al. (2011) Derivation of human parthenogenetic stem cell lines. *Methods Mol Biol*. 767:37–54.
- Daughtry B, Mitalipov S. (2014) Concise review: parthenote stem cells for regenerative medicine: genetic, epigenetic, and developmental features. *Stem Cells Transl Med*. 3:290–8.
- Wilkinson LS, Davies W, Isles AR. (2007) Genomic imprinting effects on brain development and function. *Nat Rev Neurosci*. 8:832–43.
- Keverne EB, Fundele R, Narasimha M, Barton SC, Surani MA. (1996) Genomic imprinting and the differential roles of parental genomes in brain development. *Brain Res Dev Brain Res*. 92:91–100.
- Dinger TC, et al. (2008) Androgenetic embryonic stem cells form neural progenitor cells in vivo and in vitro. *Stem Cells*. 26:1474–83.
- Ahmad R, et al. (2012) Functional neuronal cells generated by human parthenogenetic stem cells. *PLoS One*. 7:e42800.
- Choi SW, et al. (2010) Two paternal genomes are compatible with dopaminergic in vitro and in vivo differentiation. *Int J Dev Biol*. 54:1755–62.
- Wolber W, et al. (2013) Phenotype and stability of neural differentiation of androgenetic murine ES cell-derived neural progenitor cells. *Cell Medicine*. 5:29–42.
- Pearl JI, Kean LS, Davis MM, Wu JC. (2012) Pluripotent stem cells: immune to the immune system? *Sci Transl Med*. 4:164ps125.
- Drukker M, et al. (2002) Characterization of the expression of MHC proteins in human embryonic stem cells. *Proc Natl Acad Sci U S A*. 99:9864–9.
- Grinnemo KH, et al. (2006) Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. *Reprod Biomed Online*. 13:712–24.
- Li L, et al. (2004) Human embryonic stem cells possess immune-privileged properties. *Stem Cells*. 22:448–56.
- Preynat-Seauve O, et al. (2009) Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells. *J Cell Mol Med*. 13:3556–69.
- Liu J, et al. (2013) Human neural stem/progenitor cells derived from embryonic stem cells and fetal nervous system present differences in immunogenicity and immunomodulatory potentials in vitro. *Stem Cell Res*. 10:325–37.
- Drukker M, et al. (2006) Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. *Stem Cells*. 24:221–9.
- Tian X, Woll PS, Morris JK, Linehan JL, Kaufman DS. (2006) Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. *Stem Cells*. 24:1370–80.
- Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. (1997) Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytotoxicity. *Proc Natl Acad Sci U S A*. 94:11520–5.
- Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. (2008) Beyond the increasing complexity of the immunomodulatory HLA-G molecule. *Blood*. 111:4862–70.
- Juriscovica A, Casper RF, MacLusky NJ, Mills GB, Librach CL. (1996) HLA-G expression during preimplantation human embryo development. *Proc Natl Acad Sci U S A*. 93:161–5.
- Maier S, Geraghty DE, Weiss EH. (1999) Expression and regulation of HLA-G in human glioma cell lines. *Transplant Proc*. 31:1849–53.
- Lafon M, et al. (2005) Modulation of HLA-G expression in human neural cells after neurotropic viral infections. *J Virol*. 79:15226–37.
- Nasef A, et al. (2007) Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. *Transplantation*. 84:231–7.
- Wiendl H. (2007) HLA-G in the nervous system. *Hum Immunol*. 68:286–93.
- LeMaoult J, et al. (2003) Biology and functions of human leukocyte antigen-G in health and sickness. *Tissue Antigens*. 62:273–84.
- Verloes A, et al. (2011) HLA-G expression in human embryonic stem cells and preimplantation embryos. *J Immunol*. 186:2663–71.
- Le Page ME, Goodridge JP, John E, Christiansen FT, Witt CS. (2014) Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-gamma responses to soluble HLA-G preparations. *J Immunol*. 192:732–40.
- Thomson JA, et al. (1998) Embryonic stem cell lines derived from human blastocysts. *Science*. 282:1145–7.
- Ström S, Holm F, Bergstrom R, Stromberg AM, Hovatta O. (2010) Derivation of 30 human embryonic stem cell lines-improving the quality. *In Vitro Cell Dev Biol Anim*. 46:337–44.
- Fürst D, et al. (2013) High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. *Blood*. 122:3220–9.
- Zhu XM, et al. (2010) Overexpression of miR-152 leads to reduced expression of human leukocyte antigen-G and increased natural killer cell mediated cytotoxicity in JEG-3 cells. *Am J Obstet Gynecol*. 202:592.e1–7.
- Ji W, et al. (2013) MicroRNA-152 targets DNA methyltransferase 1 in NiS-transformed cells via a feedback mechanism. *Carcinogenesis*. 34:446–53.
- Rohde C, Zhang Y, Reinhardt R, Jeltsch A. (2010) BISMA-fast and accurate bisulfite sequencing data analysis of individual clones from unique and repetitive sequences. *BMC Bioinformatics*. 11:230.
- Burt D, Johnston D, Rinke de Wit T, Van den Elsen P, Stern PL. (1991) Cellular immune recognition of HLA-G-expressing choriocarcinoma cell line Jeg-3. *Int J Cancer Suppl*. 6:117–22.
- Ljunggren HGK, K. (1990) In search of the 'missing self': MHC molecules and NK cell recognition. *Immunol Today*. 11:237–44.
- Zhu Y, et al. (2012) DA neurons derived from hES cells that express HLA-G1 are capable of immunosuppression. *Brain Res*. 1437:134–42.
- Manaster I, et al. (2012) MiRNA-mediated control of HLA-G expression and function. *PLoS One*. 7:e33395.

43. Bock C, *et al.* (2011) Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. *Cell*. 144:439–52.
44. Hiby SE, King A, Sharkey A, Loke YW. (1999) Molecular studies of trophoblast HLA-G: polymorphism, isoforms, imprinting and expression in preimplantation embryo. *Tissue Antigens*. 53:1–13.
45. Hviid TVF, Møller C, Sørensen S, Morling N. (1998) Co-dominant expression of the HLA-G gene and various forms of alternatively spliced HLA-G mRNA in human first trimester trophoblast. *Hum. Immunology*. 59:87–98.
46. Zheng X, Chopp M, Lu Y, Buller B, Jiang F. (2013) MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. *Cancer Lett*. 329:146–54.
47. Veit TD, Chies JA. (2009) Tolerance versus immune response — microRNAs as important elements in the regulation of the HLA-G gene expression. *Transpl. Immunol*. 20:229–31.
48. Menier C, *et al.* (2004) Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. *Blood* 104:3153–60.
49. Stridh P, *et al.* (2014) Parent-of-origin effects implicate epigenetic regulation of experimental autoimmune encephalomyelitis and identify imprinted Dlk1 as a novel risk gene. *PLoS. Genet*. 10:e1004265.
50. Elmer BM, McAllister AK. (2012) Major histocompatibility complex class I proteins in brain development and plasticity. *Trends Neurosci*. 35:660–70.
51. Wiendl H, *et al.* (2005) Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. *Brain*. 128:2689–704.
52. Hickey WF. (2001) Basic principles of immunological surveillance of the normal central nervous system. *Glia*. 36:118–24.
53. Yen BL, *et al.* (2009) Brief report—human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. *Stem Cells*. 27:451–6.
54. Pluchino S, Cossetti C. (2013) How stem cells speak with host immune cells in inflammatory brain diseases. *Glia*. 61:1379–401.
55. Bommireddy R, *et al.* (2009) Calcineurin deficiency decreases inflammatory lesions in transforming growth factor beta1-deficient mice. *Clin. Exp. Immunol*. 158:317–24.
56. Ubiali F, *et al.* (2007) Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation. *Int. Immunol*. 19:1063–74.
57. Bonnamain V, *et al.* (2012) Expression of heme oxygenase-1 in neural stem/progenitor cells as a potential mechanism to evade host immune response. *Stem Cells*. 30:2342–53.
58. Wang L, *et al.* (2009) Neural stem/progenitor cells modulate immune responses by suppressing T lymphocytes with nitric oxide and prostaglandin E2. *Exp. Neurol*. 216:177–83.
59. Carletti B, Piemonte F, Rossi F. (2011) Neuroprotection: the emerging concept of restorative neural stem cell biology for the treatment of neurodegenerative diseases. *Curr. Neuropharmacol*. 9:313–7.
60. Lindvall O, Barker RA, Brustle O, Isacson O, Svendsen CN. (2012) Clinical translation of stem cells in neurodegenerative disorders. *Cell Stem Cell*. 10:151–5.

Cite this article as: Schmitt J, *et al.* (2015) Human parthenogenetic embryonic stem cell-derived neural stem cells express HLA-G and show unique resistance to NK cell-mediated killing. *Mol. Med*. 21:185–96.